TBPH
Theravance Biopharma Inc
NASDAQ · Pharmaceuticals
$20.48
+0.90 (+4.60%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 66.79M | 63.49M | 605.82M | 591.55M | 658.39M |
| Net Income | -58,526,658 | -50,070,334 | 94.40M | 75.68M | 89.76M |
| EPS | — | — | — | — | — |
| Profit Margin | -87.6% | -83.3% | 15.6% | 12.8% | 13.6% |
| Rev Growth | +5.2% | +5.2% | +6.8% | +8.8% | -5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 76.45M | 76.45M | 558.73M | 481.91M | 528.63M |
| Total Equity | 442.43M | 442.43M | 435.38M | 471.86M | 413.39M |
| D/E Ratio | 0.17 | 0.17 | 1.28 | 1.02 | 1.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -46,927,738 | -42,377,710 | 130.00M | 125.32M | 145.74M |
| Free Cash Flow | — | — | 125.40M | 94.80M | 134.21M |